FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2801445912> ?p ?o ?g. }

• W2801445912 endingPage "2656" @default.
• W2801445912 startingPage "2647" @default.
• W2801445912 abstract "Endocrine therapy is the cornerstone treatment for patients with hormone receptor-positive advanced breast cancer. We aimed to assess the effectiveness of various first-line endocrine monotherapies or combinations to determine the optimal sequence in a network meta-analysis.We searched PubMed, EMBASE, and the Cochrane Library for randomized controlled trials (RCTs) from inception up to November 21, 2017. We included only RCTs that assessed the effectiveness of the following treatments as a monotherapy or in combination as the first-line treatment: tamoxifen, anastrozole, letrozole, exemestane, fulvestrant, palbociclib, and ribociclib. The results were presented with pooled odds ratio or hazard ratio (HR), and 95% credible interval (CrI). The primary outcomes were objective response rate (ORR) and progression-free survival/time to progression.A total of 16 eligible articles (14 RCTs) involving 6,602 patients treated with 10 different first-line endocrine therapies were assessed in our network meta-analysis. Palbociclib plus letrozole was superior to anastrozole, letrozole, exemestane, fulvestrant 500 mg, and anastrozole plus fulvestrant (loading dose) (HR=0.44, 95% CrI: 0.33-0.58; HR=0.56, 95% CrI: 0.45-0.68; HR=0.45, 95% CrI: 0.32-0.61; HR=0.58, 95% CrI: 0.42-0.81; HR=0.50, 95% CrI: 0.37-0.68; respectively). However, there is no significant advantage compared with ribociclib plus letrozole (HR=1.00, 95% CrI: 0.72-1.39). In terms of ORR, ribociclib plus letrozole is more effective than palbociclib plus letrozole (odds ratio=1.30, 95% CrI: 0.83-2.02).Palbociclib plus letrozole and ribociclib plus letrozole might be the optimal first-line endocrine therapeutic choices for hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer due to a longer progression-free survival/time to progression and a more efficacious ORR." @default.
• W2801445912 created "2018-05-17" @default.
• W2801445912 creator A5008008825 @default.
• W2801445912 creator A5009904992 @default.
• W2801445912 creator A5025666746 @default.
• W2801445912 creator A5027151363 @default.
• W2801445912 creator A5041744189 @default.
• W2801445912 creator A5044677624 @default.
• W2801445912 creator A5072915412 @default.
• W2801445912 creator A5076895647 @default.
• W2801445912 creator A5078227951 @default.
• W2801445912 creator A5079351549 @default.
• W2801445912 creator A5085240510 @default.
• W2801445912 date "2018-05-01" @default.
• W2801445912 modified "2023-10-13" @default.
• W2801445912 title "Effect of first-line endocrine therapy in patients with hormone-sensitive advanced breast cancer: a network meta-analysis" @default.
• W2801445912 cites W1271389891 @default.
• W2801445912 cites W1617328014 @default.
• W2801445912 cites W1918073772 @default.
• W2801445912 cites W1932574503 @default.
• W2801445912 cites W1967315119 @default.
• W2801445912 cites W1994783207 @default.
• W2801445912 cites W2010699829 @default.
• W2801445912 cites W2032144589 @default.
• W2801445912 cites W2032920306 @default.
• W2801445912 cites W2071715291 @default.
• W2801445912 cites W2098270787 @default.
• W2801445912 cites W2098923148 @default.
• W2801445912 cites W2104561097 @default.
• W2801445912 cites W2113144077 @default.
• W2801445912 cites W2126945850 @default.
• W2801445912 cites W2127287298 @default.
• W2801445912 cites W2129958055 @default.
• W2801445912 cites W2131199058 @default.
• W2801445912 cites W2132846837 @default.
• W2801445912 cites W2133764838 @default.
• W2801445912 cites W2144790402 @default.
• W2801445912 cites W2158600871 @default.
• W2801445912 cites W2160584021 @default.
• W2801445912 cites W2168030291 @default.
• W2801445912 cites W2341704440 @default.
• W2801445912 cites W2508460892 @default.
• W2801445912 cites W2528767298 @default.
• W2801445912 cites W2552099557 @default.
• W2801445912 cites W2558360748 @default.
• W2801445912 cites W2560635244 @default.
• W2801445912 cites W2588681363 @default.
• W2801445912 cites W2610563129 @default.
• W2801445912 cites W2624918496 @default.
• W2801445912 cites W2737256970 @default.
• W2801445912 cites W2740803632 @default.
• W2801445912 cites W2747078758 @default.
• W2801445912 cites W2750328162 @default.
• W2801445912 cites W2917837889 @default.
• W2801445912 cites W4230263812 @default.
• W2801445912 doi "https://doi.org/10.2147/ott.s165681" @default.
• W2801445912 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5951224" @default.
• W2801445912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29780257" @default.
• W2801445912 hasPublicationYear "2018" @default.
• W2801445912 type Work @default.
• W2801445912 sameAs 2801445912 @default.
• W2801445912 citedByCount "8" @default.
• W2801445912 countsByYear W28014459122019 @default.
• W2801445912 countsByYear W28014459122020 @default.
• W2801445912 countsByYear W28014459122021 @default.
• W2801445912 countsByYear W28014459122022 @default.
• W2801445912 crossrefType "journal-article" @default.
• W2801445912 hasAuthorship W2801445912A5008008825 @default.
• W2801445912 hasAuthorship W2801445912A5009904992 @default.
• W2801445912 hasAuthorship W2801445912A5025666746 @default.
• W2801445912 hasAuthorship W2801445912A5027151363 @default.
• W2801445912 hasAuthorship W2801445912A5041744189 @default.
• W2801445912 hasAuthorship W2801445912A5044677624 @default.
• W2801445912 hasAuthorship W2801445912A5072915412 @default.
• W2801445912 hasAuthorship W2801445912A5076895647 @default.
• W2801445912 hasAuthorship W2801445912A5078227951 @default.
• W2801445912 hasAuthorship W2801445912A5079351549 @default.
• W2801445912 hasAuthorship W2801445912A5085240510 @default.
• W2801445912 hasBestOaLocation W28014459121 @default.
• W2801445912 hasConcept C121608353 @default.
• W2801445912 hasConcept C126322002 @default.
• W2801445912 hasConcept C143998085 @default.
• W2801445912 hasConcept C156957248 @default.
• W2801445912 hasConcept C168563851 @default.
• W2801445912 hasConcept C207103383 @default.
• W2801445912 hasConcept C2775860665 @default.
• W2801445912 hasConcept C2775930923 @default.
• W2801445912 hasConcept C2776215463 @default.
• W2801445912 hasConcept C2776999253 @default.
• W2801445912 hasConcept C2777176818 @default.
• W2801445912 hasConcept C2778812593 @default.
• W2801445912 hasConcept C2779744173 @default.
• W2801445912 hasConcept C2780482068 @default.
• W2801445912 hasConcept C44249647 @default.
• W2801445912 hasConcept C530470458 @default.
• W2801445912 hasConcept C71924100 @default.
• W2801445912 hasConceptScore W2801445912C121608353 @default.
• W2801445912 hasConceptScore W2801445912C126322002 @default.

• next